Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (11-20 of 367) with videos related to

Pageof 37
Sort By:
Lancet (London, England)|April 9, 2019
Pembrolizumab for all PD-L1-positive NSCLCEgbert F Smit, Adrianus J de Langen
Lancet (London, England)|August 9, 2025
Adagrasib for KRAS<sup>G12C</sup> mutated advanced non-small-cell lung cancerEgbert F Smit, Anne-Marie C Dingemans
Therapeutic Advances in Medical Oncology|July 27, 2011
Angiogenesis inhibitors in the treatment of non-small cell lung cancerJoline S W Lind, Egbert F Smit
Lancet (London, England)|March 15, 2016
PD-L1 in non-small-cell lung cancer: the third target for immunotherapyEgbert F Smit, Michel M van den Heuvel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2017
Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best BiomarkerEgbert F Smit, John B A G Haanen
Lung Cancer (Amsterdam, Netherlands)|December 10, 2014
Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case reportWouter W Mellema, Sjaak A Burgers, Egbert F Smit
The New England Journal of Medicine|April 27, 2012
Bevacizumab in neoadjuvant treatment for breast cancerAstrid A M van der Veldt, Egbert F Smit
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancerJoline S W Lind, Suresh Senan, Egbert F Smit
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
PD-L1 IHC in NSCLC with a global and methodological perspectiveErik Thunnissen, Adrianus J de Langen, Egbert F Smit
The New England Journal of Medicine|May 4, 2022
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. ReplyBob T Li, Egbert F Smit, Pasi A Jänne
Pageof 37

Showing results (11-20 of 367) with videos related to

Sort By:
Pageof 37
Lancet (London, England)|April 9, 2019
Pembrolizumab for all PD-L1-positive NSCLCEgbert F Smit, Adrianus J de Langen
Lancet (London, England)|August 9, 2025
Adagrasib for KRAS<sup>G12C</sup> mutated advanced non-small-cell lung cancerEgbert F Smit, Anne-Marie C Dingemans
Therapeutic Advances in Medical Oncology|July 27, 2011
Angiogenesis inhibitors in the treatment of non-small cell lung cancerJoline S W Lind, Egbert F Smit
Lancet (London, England)|March 15, 2016
PD-L1 in non-small-cell lung cancer: the third target for immunotherapyEgbert F Smit, Michel M van den Heuvel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2017
Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best BiomarkerEgbert F Smit, John B A G Haanen
Lung Cancer (Amsterdam, Netherlands)|December 10, 2014
Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case reportWouter W Mellema, Sjaak A Burgers, Egbert F Smit
The New England Journal of Medicine|April 27, 2012
Bevacizumab in neoadjuvant treatment for breast cancerAstrid A M van der Veldt, Egbert F Smit
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancerJoline S W Lind, Suresh Senan, Egbert F Smit
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
PD-L1 IHC in NSCLC with a global and methodological perspectiveErik Thunnissen, Adrianus J de Langen, Egbert F Smit
The New England Journal of Medicine|May 4, 2022
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. ReplyBob T Li, Egbert F Smit, Pasi A Jänne
Pageof 37